BOSTON, Sept. 08, 2020 (GLOBE NEWSWIRE) -- Akouos, Inc. (“Akouos”) (NASDAQ: AKUS), a precision genetic medicine company dedicated to developing potential gene therapies for individuals living with disabling hearing loss worldwide, today announced that Manny Simons, Ph.D., M.B.A., CEO, President and

- Upsized IPO in June 2020 raised $244.4 million in gross proceeds - - Company plans to advance lead product candidate, AK-OTOF, for the treatment of hearing loss due to mutations in the OTOF gene, to IND submission in 2021 and advance development programs spanning multiple inner ear disorders -

Alan Smith, Ph.D., Joins as Chief Technology Officer Saira Ramasastry Joins Board of Directors; Arthur Tzianabos, Ph.D., Role Expanded to Chairman BOSTON, Aug. 05, 2020 (GLOBE NEWSWIRE) -- Akouos, Inc. (“Akouos”) (Nasdaq: AKUS), a precision genetic medicine company dedicated to developing potential

BOSTON , Aug. 03, 2020 (GLOBE NEWSWIRE) -- Akouos, Inc. (“Akouos”) (NASDAQ: AKUS), a precision genetic medicine company dedicated to developing potential gene therapies for people worldwide who live with disabling hearing loss, today announced that Manny Simons , Ph.D., M.B.A., CEO, President and

BOSTON , June 30, 2020 (GLOBE NEWSWIRE) -- Akouos, Inc. (“Akouos”) (Nasdaq: AKUS), a precision genetic medicine company dedicated to developing gene therapies with the potential to restore, improve, and preserve high-acuity physiologic hearing for people worldwide who live with disabling hearing

BOSTON, June 25, 2020 (GLOBE NEWSWIRE) -- Akouos, Inc. (“Akouos”) (Nasdaq: AKUS), a precision genetic medicine company dedicated to developing gene therapies with the potential to restore, improve, and preserve high-acuity physiologic hearing for people worldwide who live with disabling hearing

Boston, Mass. – May 11, 2020 – Akouos, a precision genetic medicine company developing gene therapies to potentially restore, improve and preserve hearing, announced today that data from its inner ear gene therapy platform will be presented during the 23rd American Society of Gene and Cell Therapy

Akouos Closes $105 Million Series B Financing Appoints Vicki Sato, Ph.D., and Heather Preston, M.D., to Board of Directors Boston, Mass. – March 3, 2020   –  Akouos, Inc. (“Akouos”), a precision genetic medicine company developing potential gene therapies to restore, improve or preserve hearing,

Boston, Mass. – January 24, 2020  –  Akouos , a precision genetic medicine company developing gene therapies to potentially improve and preserve hearing, announced today that data from its inner ear gene therapy platform will be presented during the 43rd Annual Midwinter Meeting of the Association

Boston, Mass. – January 9, 2020  – Akouos, a precision genetic medicine company developing potential gene therapies to restore and preserve hearing, today announced two key senior leadership appointments. Morgan Molloy joins the team as chief corporate development officer, and Karoline Shair,